OMega-3 Fatty Acid for the Immune Modulation of Colorectal Cancer
Ontology highlight
ABSTRACT: This is a prospective, double-blind, placebo-controlled, randomized clinical trial to assess the effects of daily 4-gram marine omega-3 polyunsaturated fatty acid (MO3PUFA), through treatment with AMR101 (VASCEPA, icosapent ethyl) on the tumor immune microenvironment and gut microbiome in patients who are diagnosed with colorectal cancer or with a colorectal mass or polyp suspected to be a cancer or advanced adenoma and will undergo surgical resection or interventional endoscopy at the Massachusetts General Hospital (MGH). It uses the novel "window-of-opportunity" clinical trial design to take advantage of the window of time between cancer/mass/polyp diagnosis and surgery to examine the effect of therapeutic agents on tumor pathologic and molecular features unperturbed by prior therapies.
DISEASE(S): Colon Cancer,Colorectal Cancer,Colorectal Neoplasms
PROVIDER: 2283363 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA